F Penault-Llorca

Summary

Affiliation: Centre Jean Perrin
Country: France

Publications

  1. doi request reprint [Strategy for molecular testing in pulmonary carcinoma]
    Frederique Penault-Llorca
    Departement de Pathologie, Centre Jean Perrin, 58, rue Montalembert, 63011 Clermont Ferrand, France Electronic address
    Ann Pathol 36:73-9. 2016
  2. pmc The association between histone 3 lysine 27 trimethylation (H3K27me3) and prostate cancer: relationship with clinicopathological parameters
    Marjolaine Ngollo
    Department of Oncogenetics, Centre Jean Perrin, CBRV, 28 Place Henri Dunant, BP 38, 63001 Clermont Ferrand, France
    BMC Cancer 14:994. 2014
  3. doi request reprint Experts' opinion: Recommendations for retesting breast cancer metastases for HER2 and hormone receptor status
    Frederique Penault-Llorca
    Centre Jean Perrin, 58 rue Montalembert, BP 392, 63011 Clermont Ferrand Cedex, France
    Breast 22:200-2. 2013
  4. ncbi request reprint Pathological and molecular diagnosis of triple-negative breast cancer: a clinical perspective
    F Penault-Llorca
    Department of Pathology, Centre Jean Perrin, Clermont Ferrand, France
    Ann Oncol 23:vi19-22. 2012
  5. pmc Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial
    Jocelyne Jacquemier
    Department of Molecular Oncology, Institut Paoli Calmettes, Centre de Recherche en Cancerologie de Marseille, UMR891 Inserm, 232, bd Ste Marguerite, Marseille, 13009, France
    Breast Cancer Res 13:R109. 2011
  6. doi request reprint [Adjuvant breast cancer: which clinical and pathological characteristics in 2007?]
    F Penault-Llorca
    Service d Anatomopathologie, Centre Jean Perrin, 58, rue Montalembert, BP 392, 63011 Clermont Ferrand Cedex, France
    Bull Cancer 97:1421-6. 2010
  7. doi request reprint Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer
    Frederique Penault-Llorca
    Department of Pathology, Centre Jean Perrin, EA 4233, Université d Allvergne Clermont 1, Clermont Ferrand 63000, France
    J Clin Oncol 27:2809-15. 2009
  8. doi request reprint Intraoperative imprint cytology examination of sentinel lymph nodes after neoadjuvant chemotherapy in breast cancer patients
    P Gimbergues
    Department of Surgery, Centre Jean Perrin, Clermont Ferrand, France
    Ann Surg Oncol 17:2132-7. 2010
  9. doi request reprint Sentinel lymph node biopsy after neoadjuvant chemotherapy is accurate in breast cancer patients with a clinically negative axillary nodal status at presentation
    P Gimbergues
    Department of Surgery, Centre Jean Perrin, Clermont Ferrand, France
    Ann Surg Oncol 15:1316-21. 2008
  10. pmc Is Nottingham prognostic index useful after induction chemotherapy in operable breast cancer?
    P Chollet
    Centre Jean Perrin, 58 rue Montalembert, BP 392, 63011 Clermont Ferrand Cedex 1, France
    Br J Cancer 89:1185-91. 2003

Detail Information

Publications76

  1. doi request reprint [Strategy for molecular testing in pulmonary carcinoma]
    Frederique Penault-Llorca
    Departement de Pathologie, Centre Jean Perrin, 58, rue Montalembert, 63011 Clermont Ferrand, France Electronic address
    Ann Pathol 36:73-9. 2016
    ..This non-invasive approach allows patients with a contraindication to perform biopsy or with non-relevant biopsies to access to molecular screening. ..
  2. pmc The association between histone 3 lysine 27 trimethylation (H3K27me3) and prostate cancer: relationship with clinicopathological parameters
    Marjolaine Ngollo
    Department of Oncogenetics, Centre Jean Perrin, CBRV, 28 Place Henri Dunant, BP 38, 63001 Clermont Ferrand, France
    BMC Cancer 14:994. 2014
    ..In addition, a data analysis was made in connection with the clinicopathological parameters...
  3. doi request reprint Experts' opinion: Recommendations for retesting breast cancer metastases for HER2 and hormone receptor status
    Frederique Penault-Llorca
    Centre Jean Perrin, 58 rue Montalembert, BP 392, 63011 Clermont Ferrand Cedex, France
    Breast 22:200-2. 2013
    ....
  4. ncbi request reprint Pathological and molecular diagnosis of triple-negative breast cancer: a clinical perspective
    F Penault-Llorca
    Department of Pathology, Centre Jean Perrin, Clermont Ferrand, France
    Ann Oncol 23:vi19-22. 2012
    ..In addition, we review the potential use of emerging biomarkers as surrogates for molecular subtypes and as a means of identifying potential responders to new therapies...
  5. pmc Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial
    Jocelyne Jacquemier
    Department of Molecular Oncology, Institut Paoli Calmettes, Centre de Recherche en Cancerologie de Marseille, UMR891 Inserm, 232, bd Ste Marguerite, Marseille, 13009, France
    Breast Cancer Res 13:R109. 2011
    ..We searched for prognostic and predictive markers for docetaxel's benefit...
  6. doi request reprint [Adjuvant breast cancer: which clinical and pathological characteristics in 2007?]
    F Penault-Llorca
    Service d Anatomopathologie, Centre Jean Perrin, 58, rue Montalembert, BP 392, 63011 Clermont Ferrand Cedex, France
    Bull Cancer 97:1421-6. 2010
    ..9%, ≤ 1 cm: 11.4%, between 1 and 2 cm: 9.0%) or for a high SBR grade (III: 24.7%, II: 12.1%, I: 3.5%). This study allowed to emphasize the prevalence of HER2 overexpression in elderly patients and for small size tumors...
  7. doi request reprint Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer
    Frederique Penault-Llorca
    Department of Pathology, Centre Jean Perrin, EA 4233, Université d Allvergne Clermont 1, Clermont Ferrand 63000, France
    J Clin Oncol 27:2809-15. 2009
    ..89; 95% CI, 0.47 to 1.66; P = .71). CONCLUSION Ki67 expression identifies a subset of patients with ER-positive breast cancer who could be sensitive to docetaxel treatment in the adjuvant setting...
  8. doi request reprint Intraoperative imprint cytology examination of sentinel lymph nodes after neoadjuvant chemotherapy in breast cancer patients
    P Gimbergues
    Department of Surgery, Centre Jean Perrin, Clermont Ferrand, France
    Ann Surg Oncol 17:2132-7. 2010
    ..In patients treated with neoadjuvant chemotherapy (NAC), studies have demonstrated the feasibility and accuracy of SLN biopsy procedure. We evaluated the validity of IC for SLN testing in patients after NAC...
  9. doi request reprint Sentinel lymph node biopsy after neoadjuvant chemotherapy is accurate in breast cancer patients with a clinically negative axillary nodal status at presentation
    P Gimbergues
    Department of Surgery, Centre Jean Perrin, Clermont Ferrand, France
    Ann Surg Oncol 15:1316-21. 2008
    ..The aim of our study was to determine clinicopathological factors that may influence the accuracy of SLN biopsy after NAC...
  10. pmc Is Nottingham prognostic index useful after induction chemotherapy in operable breast cancer?
    P Chollet
    Centre Jean Perrin, 58 rue Montalembert, BP 392, 63011 Clermont Ferrand Cedex 1, France
    Br J Cancer 89:1185-91. 2003
    ....
  11. doi request reprint Comparison of dysplasia profiles in stimulated ovaries and in those with a genetic risk for ovarian cancer
    J Dauplat
    Department of Surgery, Centre Jean Perrin, Clermont Ferrand, France
    Eur J Cancer 45:2977-83. 2009
    ..In light of Fathalla's incessant ovulation theory, this study was set up to describe the presence of ovarian abnormalities (dysplasia) after ovulation induction and to compare dysplasia profiles in stimulated and genetic risk ovaries...
  12. ncbi request reprint Correlation between molecular metastases in sentinel lymph nodes of breast cancer patients and St Gallen risk category
    P Gimbergues
    Department of Surgery, Centre Jean Perrin, Clermont Ferrand, France
    Eur J Surg Oncol 33:16-22. 2007
    ..To evaluate the clinical significance of tumour metastases detected using real-time reverse transcription-PCR (RT-PCR) in sentinel lymph nodes (SLN) of breast cancer patients...
  13. ncbi request reprint Does survival increase in metastatic breast cancer with recently available anticancer drugs?
    C Abrial
    Bureau de Recherche Clinique, Centre Jean Perrin, Clermont Ferrand, France
    Oncol Res 15:431-9. 2006
    ..The sequential treatment of tamoxifen then aromatase inhibitors is presently discussed as a possible standard when used as adjuvant treatment. This sequential effect could also constitute a valuable concept for metastatic patients...
  14. pmc Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate
    S Amat
    Centre Jean Perrin, 58 rue Montalembert, 63011 Clermont Ferrand Cedex 1, France
    Br J Cancer 88:1339-45. 2003
    ..Docetaxel monotherapy is a highly effective regimen that merits formal comparison with currently used combination regimens in a randomised phase III study...
  15. ncbi request reprint Tumor parameters, clinical and pathological responses, medical management, and survival through time on 710 operable breast cancers
    C Abrial
    Centre Jean Perrin, 58 rue Montalembert, BP 392, 63011 Clermont Ferrand Cedex 1, France
    Med Oncol 22:233-40. 2005
    ..Finally, no significant difference was found when we compared overall and disease-free survival through the four periods. It appears that the progressive increase of tumor burden was compensated by more effective treatments...
  16. doi request reprint [Don't forget fallopian tubes! A morphologic and immunohistochemical study about Fallopian tubes with genetic risk (BRCA mutation)]
    G Chene
    Département d anatomopathologie, Centre Jean Perrin, boulevard Montalembert, 63000 Clermont Ferrand, France
    Gynecol Obstet Fertil 40:14-8. 2012
    ..The objective of this study was to describe morphologic and immunohistochemical features of precursor tubal lesions in prophylactically removed Fallopian tubes...
  17. doi request reprint [Intraoperative determination of axillary node metastasis by RT-PCR]
    M C Baranzelli
    Centre Oscar Lambret, 3, rue Frédérique Combemale, 59020 Lille Cedex, France, Centre Jean Perrin, boulevard Trudaine, 63000 Clermont Ferrand, France
    Bull Cancer 97:349-55. 2010
    ..The intraoperative determination of axillary node micrometastasis according to the Rapid GeneSearch Breast Lymph Node (BLN) is based on RT-PCR (mRNA of mammaglobine and CK19) detects metastases > 0.2 mm...
  18. ncbi request reprint Achieving higher pathological complete response rates in HER-2-positive patients with induction chemotherapy without trastuzumab in operable breast cancer
    Frederique Penault-Llorca
    Centre Jean Perrin, Clermont Ferrand, France
    Oncologist 12:390-6. 2007
    ..Finally, there was a tendency toward a higher DFS rate for HER-2-positive patients who achieved a pCR compared with HER-2-positive patients who did not...
  19. doi request reprint p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes
    F C Bidard
    Department of Pathology, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 19:1261-5. 2008
    ..We analysed the efficacy of a preoperative combination between 5-fluorouracil, anthracyclines and cyclophosphamide according to both p53 status and molecular classification...
  20. doi request reprint Involvement of adiponectin and leptin in breast cancer: clinical and in vitro studies
    T Jarde
    université Clermont 1, UFR Pharmacie, EA4233, CLARA, CRNH A, Clermont Ferrand, France
    Endocr Relat Cancer 16:1197-210. 2009
    ..In conclusion, the current study indicates an interaction of leptin- and adiponectin-signaling pathways in MCF-7 cancer cells whose proliferation is stimulated by leptin and suppressed by adiponectin...
  21. ncbi request reprint [Assessment of different histoprognosis grading systems for primary ovarian cancer: 100 patients given the same treatment for primary ovarian adenocarcinoma]
    F Penault-Llorca
    Centre Jean Perrin, BP 392, 63011 Clermont Ferrand Cedex
    J Gynecol Obstet Biol Reprod (Paris) 29:548-54. 2000
    ..Numerous grading systems have been proposed for invasive ovarian epithelial carcinoma. But, conflicting reports have been published addressing the value of grade as an independent prognostic factor...
  22. ncbi request reprint Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome
    Frederique Penault-Llorca
    Department of Pathology, Centre Jean Perrin, BP 392, 63011 Clermont Ferrand Cedex, France
    Int J Oncol 22:1319-25. 2003
    ..P53 and Ki67 significantly increased after treatment (p<0.005 and p<0.0005). SBR grade, proliferation markers, ER evaluated before and after treatment predicted disease-free survival (DFS) in univariate analysis...
  23. doi request reprint Tu-be or not tu-be: that is the question… about serous ovarian carcinogenesis
    G Chene
    Department of Histopathology, Centre Jean Perrin, Clermont Ferrand, France Department of Surgery, Centre Jean Perrin, Clermont Ferrand, France Department of Obstetrics and Gynecology, CHU St Etienne, France Electronic address
    Crit Rev Oncol Hematol 88:134-43. 2013
    ..In view of the recent pathological and molecular studies, we propose to discuss the genesis of high-grade serous ovarian cancer. ..
  24. doi request reprint [Ovarian epithelial dysplasia: myth or reality? Review]
    G Chene
    Departement de Chirurgie, Centre Jean Perrin, rue Montalembert, 63000 Clermont Ferrand, France
    Gynecol Obstet Fertil 36:800-7. 2008
    ..However, dysplasia in relation with ovulation induction seems to have a different pattern. We report dysplasia definitions and the current clinical management...
  25. pmc Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?
    L Arnould
    Department of Pathology, Centre G F Leclerc, Dijon 21000, France
    Br J Cancer 94:259-67. 2006
    ..These results suggest that trastuzumab plus taxanes lead to enhanced NK cell activity, which may partially account for the synergistic activity of trastuzumab and docetaxel in breast cancer...
  26. ncbi request reprint p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes
    F Bidard
    Institut Gustave Roussy, Vilejuif, France Centre Jean Perrin, Clermont Ferrand, France
    J Clin Oncol 26:608. 2008
    ..We analyzed the efficacy of a preoperative combination between 5-fluorouracil, anthracyclines and cyclophosphamide according to both p53 status and molecular classification...
  27. ncbi request reprint Preferential pathologic complete response (pCR) in HER-2 positive and triple-negative breast cancer to sequential FEC 100- docetaxel (T) neoadjuvant chemotherapy (NCT) in stage II-III operable breast cancer
    P Dubray
    Centre Jean Perrin, Clermont Ferrand, France
    J Clin Oncol 27:e11502. 2009
    ..J Clin Oncol, 2006) FEC followed by T significantly improved 5 years overall survival rates (90.7%) compared to 6 FEC 100 in node-positive breast cancer. However this combination has not yet been evaluated in NCT...
  28. ncbi request reprint Zinc-alpha2-glycoprotein: a new biomarker of breast cancer?
    V Dubois
    Faculte de Pharmacie, Laboratoire SVFp, 28 Place Henri Dunant, B P 38, 63000 Clermont Ferrand, France
    Anticancer Res 30:2919-25. 2010
    ..It is established that adipocyte secretions, i.e. adipokines, may play a role in mammary carcinogenesis. We have shown that two major adipokines, leptin and adiponectin, were expressed in mammary adenocarcinoma...
  29. doi request reprint Clinicopathological factors and nomograms predicting nonsentinel lymph node metastases after neoadjuvant chemotherapy in breast cancer patients
    P Gimbergues
    Department of Surgery, Centre Jean Perrin, Clermont Ferrand, France
    Ann Surg Oncol 16:1946-51. 2009
    ..Our goal was to determine clinicopathological factors correlating with the presence of non-SLN metastases in patients after NAC and to assess the validity of nomograms predicting additional axillary metastases...
  30. ncbi request reprint [Uterine sarcoma in patients receiving tamoxifen therapy. Apropos of 2 cases]
    G Le Bouedec
    Service de Chirurgie, centre régional de lutte contre le cancer Jean Perrin, 58, rue Montalembert, B P 392, 63011 Clermont Ferrand, France
    Rev Med Interne 22:881-5. 2001
    ....
  31. ncbi request reprint High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer
    Sophie Amat
    Centre Jean Perrin, 58 rue Montalembert, BP 392, 63011 Clermont Ferrand Cedex 1, France
    Breast Cancer Res Treat 94:255-63. 2005
    ..It is concluded that, outside any other 'biological' factor, residual disease in breast and nodes must be strongly considered after an induction chemotherapy so as to choose adjuvant treatment for the individual patient...
  32. ncbi request reprint [Is there still a place for extemporaneous exam in breast cancer?]
    T Michy
    Service de chirurgie carcinologique, Centre Jean Perrin, Place Henri Dunant, 63000 Clermont Ferrand, France
    Gynecol Obstet Fertil 34:115-9. 2006
    ..The purpose of this study is to know if extemporaneous exams still have a place in the management of breast cancer...
  33. ncbi request reprint Results on quality assurance of fluorescence in situ hybridization (FISH) technique by reference centers for HER2 status determination in metastatic breast cancer (MBC): FISH 2002 study
    F Penault-Llorca
    Centre Jean Perrin, Clermont Ferrand, France Hôpitaux Universitaires de Strasbourg, Strasbourg, France Centre G F Leclerc, Dijon, France Institut Curie, Paris, France Institut Bergonié, Bordeaux, France Centre Oscar Lambret, Lille, France CHU Dupuytren, Limoges, France Centre Leon Berard, Lyon, France CLCC Francois Baclesse, Caen, France
    J Clin Oncol 26:22028. 2008
    ..All samples were tested by FISH at regional centers [results presented SABCS 2006]. The second part of the study comprised a quality assurance study of the FISH techniques...
  34. ncbi request reprint Comparison between two prognostic index: Nottingham index (NPI) and an alternative index based on log of nodal involvement (Lpi)
    C Abrial
    Centre Jean Perrin, Clermont Ferrand, France
    J Clin Oncol 26:22146. 2008
    ..We previously showed that the residual tumour in breast and nodes confers a determinant prognosis significance (Chollet BJC, 89: 1185, 2003)...
  35. doi request reprint [Early detection of ovarian cancer: tomorrow? A review]
    G Chene
    Departement de Chirurgie, Centre Jean Perrin, 58 rue Montalembert, 63000 Clermont Ferrand, France
    J Gynecol Obstet Biol Reprod (Paris) 42:5-11. 2013
    ..Precursor lesions have at least been discovered. This review will describe in details specific features of tubal and ovarian preinvasive lesions and the old and novel techniques that could be used for early detection of ovarian cancer...
  36. ncbi request reprint [Micrometastatic disease and residual axillary disease. Breast cancer as an example Alct]
    F Penault-Llorca
    Departement de Pathologie, Centre Jean Perrin, 58, rue Montalembert, BP 392, 63011 Clermont Ferrand Cedex 01, France
    Cancer Radiother 10:338-42. 2006
    ..We have to learn how to evaluate accurately those new parameters to treat the best way our patients...
  37. ncbi request reprint [Mixed müllerian tumours of the endometrium. About four cases developed on tamoxifen treatment]
    G Le Bouedec
    Service de Chirurgie, Centre de Lutte Contre le Cancer Jean Perrin, 58, rue Montalembert, BP 392, 63011 Clermont Ferrand Cedex 1, France
    Gynecol Obstet Fertil 31:733-8. 2003
    ..There is no consensus regarding internal surveillance of women receiving tamoxifen. The usefulness of pelvic sonography has not been demonstrated...
  38. pmc Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer
    P Chollet
    Centre Jean Perrin, Bureau de Recherche Clinique, 58 rue Montalembert, B P 392, 63011 Clermont Ferrand Cedex 1, France
    Br J Cancer 86:1041-6. 2002
    ....
  39. ncbi request reprint Pathologic complete response (pCR) in HER2 positive breast cancer to sequential FEC 100-docetaxel (D) plus trastuzumab (T) neoadjuvant chemotherapy (NCT)
    P J Chollet
    Centre Jean Perrin, Clermont Ferrand, France Centre Jean Perrin, Clermont Ferrand, France
    J Clin Oncol 27:e11560. 2009
    ..Recent trials have shown higher pCR rates in Her2-positive tumors with trastuzumab-driven combinations (Buzdar, JCO 2005; Coudert, Ann Oncol, 2006). The purpose of this study was to review efficacity of sequential FEC followed by D+T...
  40. doi request reprint [Ovarian carcinogenesis: recent and past hypotheses]
    G Chene
    Departement de Chirurgie, Centre Jean Perrin, Clermont Ferrand, France
    Gynecol Obstet Fertil 39:216-23. 2011
    ..Moreover, molecular genetic analysis has designed two main pathways of tumorogenesis. In this review, we discuss the different and perhaps complementary hypotheses about ovarian carcinogenesis...
  41. doi request reprint Impact of immunohistochemical markers, CK5/6 and E-cadherin on diagnostic agreement in non-invasive proliferative breast lesions
    G MacGrogan
    Department of Pathology, Institut Bergonie, Bordeaux, France
    Histopathology 52:689-97. 2008
    ..To assess the impact of cytokeratin (CK) 5/6 and E-cadherin immunohistochemistry on diagnostic agreement of non-invasive proliferative breast lesions...
  42. doi request reprint [Update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France]
    Frederique Penault-Llorca
    Centre Jean Perrin, Departement de Pathologie, 58, rue Montalembert, 63011 Clermont Ferrand, France
    Ann Pathol 30:357-73. 2010
    ..Once acquired, this knowledge must be perpetuated by the observation of rules of good technical practice (internal and external controls, quality assurance programs)...
  43. ncbi request reprint Single static view 99mTc-sestamibi scintimammography predicts response to neoadjuvant chemotherapy and is related to MDR expression
    Anne Cayre
    Department of Pathology, Centre Jean Perrin, Clermont Ferrand, France
    Int J Oncol 20:1049-55. 2002
    ..05) in invasive ductal carcinoma. A pre-treatment single-view 99mTc-sestamibi scintimammography is an excellent predictor of MDR1 chemoresistance and was highly specific of a lack of pathological response to chemotherapy...
  44. doi request reprint Emerging technologies for assessing HER2 amplification
    Frederique Penault-Llorca
    Department de Pathologie, Centre Jean Perrin, 63011 Clermont Ferrand Cedex, France
    Am J Clin Pathol 132:539-48. 2009
    ..Moreover, signals do not decay over time. This review discusses recent publications regarding CISH and SISH testing, including results scoring and concordance between FISH and immunohistochemical analysis...
  45. pmc aHIF but not HIF-1alpha transcript is a poor prognostic marker in human breast cancer
    Anne Cayre
    Department of Pathology and INSERM U484, Centre Jean Perrin, Clermont Ferrand, France
    Breast Cancer Res 5:R223-30. 2003
    ..A natural antisense transcript (aHIF) complementary to the 3'-untranslated region of HIF-1alpha mRNA was described recently...
  46. ncbi request reprint Pathological and clinical response of a primary chemotherapy regimen combining vinorelbine, epirubicin, and paclitaxel as neoadjuvant treatment in patients with operable breast cancer
    Catherine Abrial
    Centre Jean Perrin, Bureau de Recherche Clinique, 58 rue Montalembert, BP 392, 63011 Clermont Ferrand Cedex 1, France
    Oncologist 10:242-9. 2005
    ..There was no case of severe cardiac toxicity, thrombocytopenia, or any other serious adverse events. In conclusion, whereas this regimen was relatively well tolerated, it appears inferior to other regimens and its use is not recommended...
  47. ncbi request reprint [Epidermal growth factor receptors: status evaluation methods and tumor expression]
    Frederique Penault-Llorca
    Centre Jean Perrin, 58, rue Montalembert, BP 392, 63011 Clermont Ferrand
    Bull Cancer 90:S186-91. 2003
    ..EGFR testing may be required before targeted treatment. An exciting endpoint would be the functional and dynamic evaluation of EGFR and downstream proteins for patients, before and during treatment...
  48. doi request reprint Capillary permeability and extracellular volume fraction in uterine cervical cancer as patient outcome predictors: measurements by using dynamic MRI spin-lattice relaxometry
    Véronique Dedieu
    Medical Physics, Department of Centre J Perrin, Clermont Ferrand, France
    J Magn Reson Imaging 27:846-53. 2008
    ..To improve the outcome prediction of uterine cervical carcinoma by measuring the vascular permeability (k(ep)) and the extracellular volume fraction (v(e)) of the tumor from Dynamic T(1)- IRM Relaxometry...
  49. ncbi request reprint [Assessment of HER2 status in breast cancer]
    Frederique Penault-Llorca
    Departement de Pathologie, Centre Jean Perrin, 58, rue Montalembert, BP 392, 63011 Clermont Ferrand
    Bull Cancer 91:S211-5. 2004
    ..The importance of adhesion to quality assurance programs is underlined. Finally, the different national testing guidelines are discussed...
  50. ncbi request reprint [EGFR expression in colorectal cancer and role in tumorigenesis]
    Frederique Penault-Llorca
    Centre Jean Perrin, 58 rue Montalembert, BP 392, 63011 Clermont Ferrand Cedex
    Bull Cancer 92:S5-11. 2005
    ..EGFR testing may be required before targeted treatment. An exciting endpoint might be the functional and dynamic evaluation of EGFR and downstream proteins for patients, before and during treatment...
  51. ncbi request reprint [New entities in pathological classification and new therapeutic options in renal cell carcinoma]
    Jacques Olivier Bay
    Departement d Oncologie Medicale, Centre Jean Perrin, 58 rue Montalembert, 63000 Clermont Ferrand
    Bull Cancer 93:91-100. 2006
    ..Finally, we will present targeted therapy (antiangiogenic drugs and tyrosine kinase inhibitors) with the mechanisms of action, efficacy and appropriate use in the treatment of metastatic renal cell carcinoma...
  52. ncbi request reprint [The pathologist and EGFR in 2004: I like you, nor do it]
    Frederique Penault-Llorca
    Centre Jean Perrin, 58 rue Montalembert, BP 392, 63011 Clermont Ferrand Cedex
    Ann Pathol 24:416-26. 2004
    ..An exciting endpoint might be the functional and dynamic evaluation of EGFR and downstream proteins, for patients, before and during treatment. The exact role of the pathologist still have to be accurately determined...
  53. ncbi request reprint [Sentinel lymph node biopsy for breast cancer after neoadjuvant chemotherapy: influence of nodal status before treatment]
    Guillaume Le Bouedec
    Service Chirurgie, Centre de Lutte Contre le Cancer d Auvergne Jean Perrin, 58, rue Montalembert, BP 392, 63011 Clermont Ferrand Cedex 1
    Bull Cancer 93:415-9. 2006
    ..To determine feasibility and accuracy of SLN biopsy in locally advanced breast cancer treated by neoadjuvant chemotherapy...
  54. ncbi request reprint [Place of anatomopathology in evaluation of response to neoadjuvant chemotherapy. Prognostic and predictive markers: example of breast cancer]
    Catherine Abrial
    Unite de recherche clinique, Centre Jean Perrin, 58, rue Montalembert, BP392, 63011 Clermont Ferrand Cedex 1
    Bull Cancer 93:663-8. 2006
    ..The evaluation of the post-treatment tumour residue helps to determine tumour response to treatment and prognosis, as well as to adjust adjuvant regimens. It is essential to standardize these histopathological procedures...
  55. ncbi request reprint Sequential addition of an anthracycline-based regimen to docetaxel as neoadjuvant chemotherapy in patients with operable breast cancer
    Sophie Amat
    Centre Jean Perrin, Clermont Ferrand, France
    Clin Breast Cancer 7:262-9. 2006
    ..The objective of this phase II study was to attempt to maximize response and survival in patients with bulky, operable breast cancer by combining sequential neoadjuvant docetaxel to a semi-intensive anthracycline-based regimen...
  56. ncbi request reprint Does 99mTc-sestamibi uptake discriminate breast tumors?
    Anne Cayre
    Department of Pathology, Centre Jean Perrin, Clermont Ferrand, France
    Cancer Invest 22:498-504. 2004
    ..005). This difference is also significant using the Cox model (p < 0.05). Uptake of 99mTc-sestamibi (low vs. high) discriminates breast tumors with different histopathological characteristics and prognosis...
  57. ncbi request reprint Is there an immunohistochemical technique definitively valid in epidermal growth factor receptor assessment?
    Frederique Penault-Llorca
    Centre Jean Perrin, Departement de Pathologie, 63011 Clermont Ferrand Cedex, France
    Oncol Rep 16:1173-9. 2006
    ..No scoring system showed, to date, its accuracy, and more studies have to be conducted with an evaluation of the response to cetuximab, possibly with a correlation with FISH amplification in colorectal carcinoma...
  58. ncbi request reprint Changes in and prognostic value of hormone receptor status in a series of operable breast cancer patients treated with neoadjuvant chemotherapy
    Olivier Tacca
    Bureau de Recherche Clinique, Centre Jean Perrin 58, rue Montalembert, BP 392, 63011 Clermont Ferrand Cedex 1, France
    Oncologist 12:636-43. 2007
    ..In this work, NCT induced variations in HR status in 23% of patients. A positive switch in HR status after NCT could be an indicator of better prognosis for patient outcome...
  59. ncbi request reprint [Targeted therapies: the question of target detection and evaluation]
    Frederique Penault-Llorca
    Centre Jean Perrin, BP392, 63011 Clermont Ferrand Cedex
    Bull Cancer 94:F245-8. 2007
    ....
  60. ncbi request reprint [Roles of the pathologist in neoadjuvant chemotherapy: evaluation of response, prognostic and predictive factors]
    Frederique Penault-Llorca
    Departement de Pathologie, Centre Jean Perrin, 58 rue Montalembert, BP 392, 63011 Clermont Ferrand Cedex 1
    Ann Pathol 23:555-63. 2003
    ..The evaluation of the post treatment tumor residue helps in determinating tumor response to treatment, establishing prognosis and adjusting adjuvant regimens. Standard histopathological procedures are mandatory...
  61. ncbi request reprint [Comments on the new American Joint Committee on Cancer TNM staging for breast cancer. What's new for the pathologist?]
    Frederique Penault-Llorca
    Departement de Pathologie, Centre Jean Perrin, 58 rue Montalembert, BP 392, 63011 Clermont Ferrand Cedex 1
    Ann Pathol 23:492-5. 2003
    ..These new parameters should help in the collection of uniform informations and in a more accurate management of breast cancer patients...
  62. ncbi request reprint [Prognostic value of epidermal growth factor receptor]
    Frederique Penault-Llorca
    Departement de Pathologie, Centre Jean Perrin, 58, rue Montalembert, BP 392, 63011 Clermont Ferrand
    Bull Cancer 90:S192-6. 2003
    ..Because of its role in oncogenesis and its prognostic value, REGF might in the future become a therapeutic target...
  63. pmc Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer
    L Arnould
    Department of Pathology, Centre GF Leclerc, 1 rue Pr Marion, 21034 Dijon Cedex, France
    Br J Cancer 88:1587-91. 2003
    ..Our results allow us to think that, in many laboratories, CISH may also be an excellent method to calibrate the IHC procedures or, as a quality control test, to check regularly that the IHC signal is in agreement with the gene status...
  64. ncbi request reprint DNA microarray analysis of gene expression profiles in deep endometriosis using laser capture microdissection
    S Matsuzaki
    Department of Gynecology, Polyclinique de l Hotel Dieu, CHU, Clermont Ferrand, France
    Mol Hum Reprod 10:719-28. 2004
    ..One of the candidate genes, MOR, may be involved in a defective immune system in endometriosis. This study has provided new insights into endometriosis pathophysiology...
  65. ncbi request reprint Interleukin-6 overexpression as a marker of malignancy in human gliomas
    C Rolhion
    Laborartoire de Transfert en Oncologie Prédictive, Centre Jean Perrin, Clermont Ferrand, France
    J Neurosurg 94:97-101. 2001
    ..This study was conducted to test this hypotheses and to evaluate the suitability of IL-6 as a target in the treatment of GBMs...
  66. pmc Comparison of different commercial kits for HER2 testing in breast cancer: looking for the accurate cutoff for amplification
    Anne Cayre
    Departement de Pathologie, Centre Jean Perrin, 58 rue Montalembert, BP392, 63011 Clermont Ferrand Cedex, France
    Breast Cancer Res 9:R64. 2007
    ..The interpretation pitfalls, optimal threshold values, assay duration and complexity of each kit were also considered...
  67. doi request reprint Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer
    J M Nabholtz
    ERTICA EA 4677, University of Auvergne, Clermont Ferrand, France
    Int J Cancer 138:2274-80. 2016
    ..Similarly to previous observations using panitumumab, another anti-EGFR antibody, the immune component of the tumor microenvironment may play an important role in predicting TNBC response to the neoadjuvant therapy...
  68. doi request reprint Anti-melanoma efficacy of internal radionuclide therapy in relation to melanin target distribution
    M Bonnet
    UMR 990 INSERM UdA Imagerie Moléculaire et Thérapie vectorisée, Clermont Ferrand, France
    Pigment Cell Melanoma Res 23:e1-11. 2010
    ..This study supports the use of melanin targeting with (131)I-labelled iodoquinoxaline for effective treatment of melanoma...
  69. doi request reprint Ovarian epithelial dysplasia after ovulation induction: time and dose effects
    G Chene
    Department of Oncology and Surgery, Centre Jean Perrin, Clermont Ferrand, France
    Hum Reprod 24:132-8. 2009
    ..Ovarian stimulation has been considered as a risk factor of ovarian cancer by Fathalla's incessant ovulation theory. In this study, we have investigated the risk of ovarian dysplasia after ovulation induction...
  70. doi request reprint Changes and predictive and prognostic value of the mitotic index, Ki-67, cyclin D1, and cyclo-oxygenase-2 in 710 operable breast cancer patients treated with neoadjuvant chemotherapy
    Frederique Penault-Llorca
    Centre Jean Perrin, Bureau de Recherche Clinique, Clermont Ferrand Cedex 1, France
    Oncologist 13:1235-45. 2008
    ..Because these factors were correlated, no multivariate model was done. The main clinical fact is that there were significant correlations between clinical and pathological responses and variations in the biological factors studied...
  71. pmc Assessment of epidermal growth factor receptor (EGFR) expression in primary colorectal carcinomas and their related metastases on tissue sections and tissue microarray
    Frederic Bibeau
    Department of Pathology, Centre Regional de Lutte contre le Cancer Val d Aurelle, 34298, Montpellier, Cedex 5, France
    Virchows Arch 449:281-7. 2006
    ..In conclusion, EGFR expression measured in tissue sections from primary CRC and their related metastases was found to be similar and frequent, but it was significantly underestimated by the TMA technique...
  72. ncbi request reprint Additional value of EGFR downstream signaling phosphoprotein expression to KRAS mutation for response prediction to cetuximab in colorectal cancer (CRC)
    J L Merlin
    Centre Alexis Vautrin, Vandoeuvre les Nancy, France Université René Descartes, Paris, France Hôpital Ambroise Paré, Paris, France Institut Gustave Roussy, Villejuif, France Centre Val d Aurelle, Montpellier, France CHU Robert Debré, Reims, France Centre Jean Perrin, Clermont Ferrand, France
    J Clin Oncol 26:4126. 2008
    ....
  73. ncbi request reprint Neoadjuvant chemotherapy (NACT) in hormone receptor-positive (HR+) or triple-negative (TN) operable breast cancer (BC): A randomized study comparing standard to response-adapted sequence
    H Cure
    Institut Jean Godinot, Reims, France Centre Jean Perrin, Clermont Ferrand, France Institut Jean Godinot, Clermont Ferrand, France
    J Clin Oncol 29:1133. 2011
    ..A new classification will assess the limited residual disease in breast and nodes (LRDBN) when obtained...
  74. ncbi request reprint [Principal therapeutic uses of monoclonal antibodies in oncology]
    F Penault-Llorca
    Centre Jean Perrin, 58, rue Montalembert, BP 392, Clermont Ferrand, France
    Cancer Radiother 6:24s-28s. 2002
    ..These examples outline the importance of the recent progress in selectively targeting tumor antigen and the potential impact of these approaches in Oncology...
  75. ncbi request reprint High inter-observer agreement in immunohistochemical evaluation of HER-2/neu expression in breast cancer: a multicentre GEFPICS study
    Magali Lacroix-Triki
    Department of Pathology, Institut Claudius Regaud, 20 24 rue du Pont saint Pierre, 31052 Toulouse Cedex, France
    Eur J Cancer 42:2946-53. 2006
    ..82). As expected, the score 2+ group showed poor agreement (kappa=0.38). A quality assurance process showed that ring studies and adherence to national guidelines greatly improve inter-observer reproducibility...
  76. ncbi request reprint O(6)-methylguanine-DNA methyl transferase gene expression and prognosis in breast carcinoma
    Anne Cayre
    Department of Pathology, Centre Jean Perrin, BP 392, 63011 Clermont Ferrand Cedex, France
    Int J Oncol 21:1125-31. 2002
    ..This difference is also significant using the COX model (p<0.05). In breast cancer, tumor MGMT expression was not predictive of response to CPM. A low MGMT expression was significantly related to poor survival...